— Novel Viscosupplement for Knee Osteoarthritis Pain—
Tokyo, Japan, December 9, 2010 ---Teijin Pharma Limited, the core company of the Teijin Group's medical and pharmaceutical business, announced today that it will launch SYNVISC (hylan G-F 20), a novel viscosupplement for the treatment of osteoarthritis knee pain, in Japan on December 14.

SYNVISC, which was developed by Genzyme Corporation in the United States, is an innovative sodium hyaluronate treatment in which cross-linked hyaluronate is injected into the knee joint to replace degraded fluid for improved lubrication. The treatment offers longer relief and fewer doses than currently available drugs. SYNVISC is marketed in more than 70 countries, including the United States, where it accounts for more than 50% of the market for intra-articular hyaluronan injections to treat knee osteoarthritis pain. More than four million people worldwide have used the treatment. SYNVISC will be the only drug in Japan to offer six months of knee pain relief from just three injections.

Genzyme Japan, a subsidiary of Genzyme Corporation, obtained approval to market SYNVISC from the Ministry of Health, Labor and Welfare this past July. An agreement granting Teijin Pharma exclusive commercialization rights to Synvisc in Japan was concluded in the following month. The two companies now aim to develop SYNVISC's presence in the local market for hyaluronan injections, estimated to be worth around 50 billion yen per annum.

Knee osteoarthritis is a typical age-related chronic disorder that can lead to pain and restricted motion due to joint degeneration associated with various causes, including deteriorated articular cartilage/meniscus, deteriorated joint fluid or weakened muscles. According to a recent Japanese epidemiological study, nearly 30 million people in Japan have the condition.

About Teijin Pharma Limited
Teijin Pharma Limited, the core company of Teijin Group's medical and pharmaceuticals business, focuses on three key therapeutic areas: respiratory, bone/joint, and cardiovascular/metabolic diseases. Teijin Pharma has strong marketing positions, particularly in the respiratory and bone/joint areas, with pharmaceutical products as well as a home healthcare business, including home oxygen therapy. Teijin Pharma continues to enhance its presence worldwide through in-house R&D as well as in-licensing and out-licensing activities. Please visit www.teijin-pharma.co.jp/english/index.html

About the Teijin Group
Based in Tokyo and Osaka, Japan, Teijin is a global technology-driven group operating in eight main fields: aramid fibers, carbon fibers, polyester fibers, plastics, films, medical & pharmaceuticals, fiber products marketing and IT businesses. Teijin Limited, the holding company for the Teijin Group, is listed on the Tokyo and Osaka stock exchanges. The group had consolidated sales of USD 8.5 billion (JPY 765.8 billion, USD 1=JPY 90) in fiscal 2009 and employs 18,778 people worldwide, with 156 companies around the world.